Search

Displaying results 4591 - 4600 of 9702 in total
  1. Drug

    Briakinumab

    go.drugbank.com/drugs/DB05459
    Investigational

    Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. … Briakinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn’s Disease and other autoimmune and inflammatory disorders.

  2. Drug

    ISS-1018

    go.drugbank.com/drugs/DB05463
    Investigational

    ISS 1018 is a short, synthetic, unmethylated CpG oligodeoxynucleotide (CpG ODN) with immunostimulatory activity. … ISS 1018 is currently being investigated in combination with HBsAg vaccine as a prophylactic treatment for to prevent Hepatitis B in adults.

  3. Drug

    WX-UK1

    go.drugbank.com/drugs/DB05476
    Investigational

    WX-UK1 is a 3-amidinophenylalanine-based non-cytotoxic small molecule that belongs to a new class of drugs. … Independent studies show that administration of Wx-UK1 resulted in a decrease of tumor cell invasion, suggesting its efficacy as a an adjuvant antimetastatic therapy of carcinomas.

  4. Drug

    PBI-1402

    go.drugbank.com/drugs/DB05480
    Experimental

    PBI-1402 has a dual therapeutic action; as a chemoprotectant and hematopoietic progenitor stimulator. … PBI-1402 is a small molecule synthetic compound with oral Bioavailability.

  5. Drug

    Otelixizumab

    go.drugbank.com/drugs/DB05496
    Investigational

    Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling.

  6. Drug

    KW-7158

    go.drugbank.com/drugs/DB05498
    Experimental

    KW-7158 is a tricyclic compound with a non-cholingergic mechanism of action for the treatment of "urinary urgency," "frequent urination" and "urinary incontinence" associated with bladder overactivity … The therapeutic effects of KW-7158 in overactive bladder may be due to the activation of A-type K(+) channels which regulate afferent neuron excitability and firing properties in the dorsal root ganglion

  7. Drug

    AVN-944

    go.drugbank.com/drugs/DB05500
    Investigational

    AVN944 is a biotech drug that demonstrated a statistically meaningful impact on IMPDH and other proteins that are critical to activities in cancer cells, including nucleotide biosynthesis, energy and metabolism

  8. Drug

    Mavorixafor

    go.drugbank.com/drugs/DB05501
    ApprovedInvestigational

    Mavorixafor is a CXC chemokine receptor 4 (CXCR4) antagonist. … by a reduced number of mature neutrophils and lymphocytes.

  9. Drug

    NM-702

    go.drugbank.com/drugs/DB05505
    Investigational

    Intermittent claudication is a major symptom of arteriosclerosis obliterans. … Nissan Chemical and Taisho have been jointly developing NM-702, a drug for the treatment of arteriosclerosis obliterans.

  10. Drug

    Belnacasan

    go.drugbank.com/drugs/DB05507
    Investigational

    VX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase-1 (VRT-043198).